There are 2789 resources available
1139P - Carcinoma of unknown primary (CUP): The role of tumor genomic profiling
Presenter: Cathleen Park
Session: ePoster Display
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Presenter: Timothy Humphries
Session: ePoster Display
1054P - FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma
Presenter: Florentia Dimitriou
Session: ePoster Display
1055P - Prognostic relevance of tumor-infiltrating lymphocytes in early-stage melanoma
Presenter: Eftychia Chatziioannou
Session: ePoster Display
1056P - Survival of patients with advanced melanoma according to first-line treatment and key prognostic factors: Real-world data from GEM1801 study
Presenter: Ivan Marquez-Rodas
Session: ePoster Display
1057P - ROS1 mutation can serve- as a potential efficacious predictor of immunotherapy in melanoma patients
Presenter: Hucheng Liu
Session: ePoster Display
1058P - Treatment outcomes with unselected autologous tumor infiltrating lymphocytes (TILs) in patients (pts) with checkpoint inhibition–refractory advanced cutaneous melanoma
Presenter: Manon Pillai
Session: ePoster Display
1092TiP - Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
Presenter: Reinhard Dummer
Session: ePoster Display
1093TiP - An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Presenter: Francesca Aroldi
Session: ePoster Display
1094TiP - A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
Presenter: Andrew Haydon
Session: ePoster Display